THE IDENTIFICATION of an individual patient's methotrexate (MTX) absorption characteristics would be of clinical value if this could be used either to anticipate toxicity or to indicate inadequate absorption. The therapeutic range of MTX blood levels is currently unknown. It is not clear whether either response or prognosis depends upon the magnitude of the peak level, the duration for which a critical level is exceeded, or the total amount of drug absorbed as indicated by the area under the absorption curve. It has recently been suggested that the rate of absorption may be an important factor, with the slow absorber having a high relapse rate (Craft, 1979 Int. Symp. Methotrexate) .
Variations in the absorption of orally administered MTX were first demonstrated by Freeman-Narrod (1962) who suggested that patients could be divided into fast and slow absorbers based upon the serum MTX level 1 h after administration. The slow absorber had a low peak level, but MTX was detectable for a prolonged period, often associated with mucosal ulceration. An association between prolonged MTX therapy and drug malabsorption has been suggested (Freeman-Narrod, 1962; Craft, 1977) since this drug is known to affect small intestinal structure (Trier, 1962) and function (Craft, 1977; Venho, 1976) .
Previous studies of MTX absorption have been poorly standardized with regard to the dose of MTX and its relationship to food and other oral medication (FreemanNarrod, 1962; Kierney, 1979; Boomla, 1979) . In this study these factors were carefully standardized, and the early serum profile of MTX was measured in a group of leukaemic children.
Twenty children with acute lymphoblastic leukaemia (ALL) were studied, 10 of whom were males. Their ages ranged from 3 to 16 years and the duration on therapy from 3 to 36 months. The timing of the peak value ranged from 0.5 to 4 h after administration, mean 1.5 h. Fig. 2 shows the absorption patterns of 6 patients (30%) who had serum levels less than 0 44 uM at 1 h and who could be classified as slow absorbers (Craft, 1979) . After 1 h there was wide variation in the absorption pattern, 3 patients reaching high peak levels which were greater than the mean for the group as a whole.
It seems clear from these observations that a lh serum MTX level may not accurately reflect the overall serum profile. In contrast to the observations of Freeman-Narrod (1962) rate of gastric emptying and small intestinal motility, as well as the rates of intravascular distribution and excretion. It may be important to determine which of these factors contribute to an early low level, if in fact the slow absorber is predisposed to early disease relapse (Craft, 1979) . A more extended analysis of the absorption/ excretion profile would provide information such as the absorption rate constant, elimination rate constant and the area under the curve. It might more logically be these derivations which would be correlated with response to therapy and rate of relapse. Moreover, although this study was carried out in the fasting state, investigation of the influences of differing nutrients taken in association with the drug is being carried out, as these may significantly alter absorption (Krondl, 1970) . On the basis of random sampling and division into fast or slow absorbers it would be unwise at present to alter methotrexate therapy either in terms of dosage or route of administration. Although information can be obtained from short-term studies such as this, it is preferable that data be obtained from a more extended study, to permit accurate pharmacokinetic analysis.
